See more : Coro Energy plc (CORO.L) Income Statement Analysis – Financial Results
Complete financial analysis of Amicus Therapeutics, Inc. (FOLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amicus Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wealth Invest Strategi Alternativer (WEISA.CO) Income Statement Analysis – Financial Results
- Henan Dayou Energy Co., Ltd (600403.SS) Income Statement Analysis – Financial Results
- J Sainsbury plc (JSNSF) Income Statement Analysis – Financial Results
- Nyxio Technologies Corporation (NYXO) Income Statement Analysis – Financial Results
- New Century Logistics (BVI) Limited (NCEW) Income Statement Analysis – Financial Results
Amicus Therapeutics, Inc. (FOLD)
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 399.36M | 329.23M | 305.51M | 260.89M | 182.24M | 91.25M | 36.93M | 4.96M | 0.00 | 1.22M | 363.00K | 18.41M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 37.33M | 38.60M | 34.47M | 31.04M | 21.96M | 14.40M | 6.24M | 833.00K | 1.83M | 0.00 | 13.49M | 20.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 362.03M | 290.63M | 271.05M | 229.84M | 160.27M | 76.84M | 30.69M | 4.13M | -1.83M | 1.22M | -13.13M | -1.97M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.65% | 88.28% | 88.72% | 88.10% | 87.95% | 84.21% | 83.11% | 83.20% | 0.00% | 100.00% | -3,616.80% | -10.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 152.38M | 276.68M | 272.05M | 308.44M | 286.38M | 270.90M | 149.31M | 104.79M | 76.94M | 47.62M | 41.94M | 50.27M | 50.86M | 39.04M | 48.08M | 37.76M | 31.07M | 33.63M | 13.65M | 0.00 | 4.43M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.20M | 0.00 | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 275.27M | 213.04M | 192.71M | 156.41M | 169.86M | 127.20M | 88.67M | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 12.28M | 6.88M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.34M | 6.21M | 8.85M | 4.78M | -5.63M | 6.01M | -4.79M | -80.00K | -77.00K | 1.72M | 21.00K | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 0.00 | 0.00 | -8.81M | 0.00 |
| Operating Expenses | 427.65M | 495.06M | 470.97M | 473.70M | 461.01M | 402.32M | 241.57M | 179.19M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Cost & Expenses | 472.85M | 533.66M | 505.43M | 504.74M | 482.98M | 416.72M | 247.81M | 180.02M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Interest Income | 7.08M | 3.02M | 509.00K | 3.23M | 10.25M | 10.46M | 4.10M | 1.60M | 929.00K | 223.00K | 174.00K | 316.00K | 160.00K | 156.00K | 997.00K | 4.82M | 0.00 | 1.99M | 609.52K | 0.00 | 5.00K |
| Interest Expense | 50.15M | 37.12M | 32.47M | 22.43M | 18.87M | 22.40M | 17.24M | 5.40M | 1.58M | 1.48M | 46.00K | 89.00K | 148.00K | 260.00K | 278.00K | 218.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.87M | 5.34M | 6.21M | 8.85M | 4.78M | 4.22M | 3.59M | 3.24M | 1.83M | 1.55M | 1.72M | 1.71M | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 952.45K | 667.38K | 0.00 | 132.00K |
| EBITDA | -92.08M | -199.58M | -202.87M | -242.98M | -332.26M | -322.47M | -428.29M | -195.14M | -128.71M | -67.01M | -61.38M | -50.24M | -46.54M | -53.76M | -4.16M | -37.64M | -44.57M | -44.70M | -20.20M | -8.81M | -6.47M |
| EBITDA Ratio | -23.06% | -58.28% | -64.19% | -89.14% | -180.52% | -346.79% | -533.94% | -3,529.85% | 0.00% | -5,471.49% | -16,611.57% | -276.41% | -229.27% | -5,816.05% | -4.19% | -283.71% | -2,489.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -73.49M | -204.43M | -199.92M | -243.85M | -300.74M | -328.78M | -441.99M | -181.89M | -130.44M | -68.70M | -64.18M | -52.93M | -50.89M | -55.84M | -7.35M | -43.96M | -45.81M | -46.86M | -20.83M | -8.81M | -6.60M |
| Operating Income Ratio | -18.40% | -62.09% | -65.44% | -93.47% | -165.03% | -360.32% | -1,196.82% | -3,668.62% | 0.00% | -5,612.83% | -17,680.72% | -287.50% | -237.41% | -6,056.18% | -11.42% | -293.69% | -2,567.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -76.61M | -37.61M | -41.63M | -30.40M | -55.17M | -23.61M | -7.14M | -21.89M | -6.07M | -1.34M | 1.04M | 901.00K | 2.85M | -237.00K | 783.00K | 4.60M | 4.64M | 514.36K | 247.27K | 0.00 | -168.00K |
| Income Before Tax | -150.10M | -242.04M | -241.55M | -274.25M | -355.91M | -349.09M | -449.12M | -203.78M | -132.12M | -70.04M | -63.15M | -52.03M | -48.04M | -56.08M | -6.57M | -39.36M | -41.17M | -46.34M | -20.58M | 0.00 | -6.77M |
| Income Before Tax Ratio | -37.59% | -73.52% | -79.06% | -105.12% | -195.30% | -382.58% | -1,216.14% | -4,110.15% | 0.00% | -5,722.14% | -17,395.32% | -282.60% | -224.13% | -6,081.89% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.48M | -5.47M | 8.91M | 2.60M | 478.00K | -94.00K | -165.12M | -3.74M | 1.50M | -1.11M | -3.51M | -3.25M | -3.63M | -1.14M | 278.00K | 0.00 | 351.00K | -514.36K | -611.80K | 8.81M | 0.00 |
| Net Income | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M | -349.00M | -284.00M | -200.04M | -132.12M | -68.93M | -59.63M | -48.79M | -44.41M | -54.94M | -6.57M | -39.36M | -41.17M | -46.34M | -19.97M | -8.81M | -6.77M |
| Net Income Ratio | -37.96% | -71.85% | -81.98% | -106.12% | -195.56% | -382.48% | -769.03% | -4,034.73% | 0.00% | -5,631.21% | -16,427.82% | -264.98% | -207.20% | -5,958.35% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| EPS Diluted | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| Weighted Avg Shares Out | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
| Weighted Avg Shares Out (Dil) | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
Amicus Therapeutics: Too Cheap At Under $10 A Share
Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth. The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction. Analyst firms are also largely positive on the...
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amicus Therapeutics, Inc. (FOLD) Q1 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - CBO Jeff Castelli - CDO Simon Harford -...
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.18 per share a year ago.
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold ® Guidance on Continued Strong Demand Strong Pombiliti ® + Opfolda ® Launch with Increasing...
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care Conference in Las Vegas, NV on Wednesday, May 15, 2024,...
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:30 a.m. ET to discuss financial results for...
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Source: https://incomestatements.info
Category: Stock Reports